Axol Bioscience and CENSO Biotechnologies enter merger agreement
pharmafile | March 17, 2021 | News story | Research and Development | Axol Bioscience, Censo Biotechnologies, immune cell, merger, neuroscience
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO focused on iPSC-related technologies, have signed a merger agreement.
The new entity will become a leading provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modelling for drug discovery and screening markets. It will offer customers validated, ready-to-use cell lines and a suite of services with broader expertise, robust functional data, and customisation capabilities, all with shorter lead times.
Axol Bioscience’s investors include Dr Jonathan Milner, Chairman of Axol’s board, and award-winning EIS fund manager Calculus Capital. CENSO Biotechnologies’ major investor is leading Edinburgh-based EIS fund manager Par Equity.
The transaction, effective today, is accompanied by a fundraising round in excess of £3.8 million, led by Calculus Capital and Par Equity. The investment will be used to enable the growth of the business and acquisition of talent to meet customer demand.
Under the terms of the agreement, Axol Bioscience’s CEO, Liam Taylor, and the Axol senior leadership team will take over the management of the combined entity, with the intent to migrate the brand to Axol Bioscience. The agreement sees CENSO’s interim CEO, Dr Tom Stratford, appointed Non-Executive Director of the combined board, on behalf of Par Equity.
Liam Taylor, CEO of Axol, said: “Axol has experienced a rapid increase in demand for their iPSC-based products and services over the last three years. Merging with CENSO immediately and significantly grows our scientific team and breadth of expertise.
“That, and the addition of two sites for iPSC-derived cell line manufacturing and custom service work, will increase our production capacity and future-proof our organisation to ensure demand can continue to be met with the short lead times and quality that our customers depend on.”
Dr Tom Stratford, CENSO’s interim CEO and Non-Executive Director of the combined board, commented: “CENSO’s strength is our scientific team, as trusted partners in designing, executing, and managing custom project work.
“The combined entity will now be able to leverage Axol’s strength in iPSC-derived cells as well as complementary services such as electrophysiology to further our ability and efficiency to serve customers. We bring to bear capabilities, bandwidth, and expertise to scale the manufacturing of those tools in a way that benefits both customer bases and the wider market.”
Darcy Jimenez
Related Content
Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology
Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to …
Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease
Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem …
Cognixion receives FDA Breakthrough Device Designation for assisted communication device
Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced …
